Never like to hear this, though the filing says he's leaving to form his own company. I'm less concerned about this I think than if he were just leaving to join another existing company. Could it be the CSO took some heat for the design of the lead tivantinib trial that bombed and decided to bolt to do his own thing?
News 
Market Data 
Discover 
AI
